Glucose-6-phosphate dehydrogenase deficiency, chlorproguanil-dapsone with artesunate and post-treatment haemolysis in African children treated for uncomplicated malaria

C. Van Malderen, J.P. Van geertruyden, S. Machevo, R. Gonzalez, Q. Bassat, A. Talisuna, A. Yeka, C. Nabasumba, P. Piola, A. Daniel, E. Turyakira, Pascale Forret, C. Van Overmeir, H. van Loen, A. Robert, Umberto D'Alessandro

Research output: Contribution to journalA1: Web of Science-article

13 Downloads (Pure)

Abstract

BACKGROUND: Malaria is a leading cause of mortality, particularly in sub-Saharan African children. Prompt and efficacious treatment is important as patients may progress within a few hours to severe and possibly fatal disease. Chlorproguanil-dapsone-artesunate (CDA) was a promising artemisinin-based combination therapy (ACT), but its development was prematurely stopped because of safety concerns secondary to its associated risk of haemolytic anaemia in glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals. The objective of the study was to assess whether CDA treatment and G6PD deficiency are risk factors for a post-treatment haemoglobin drop in African children
Original languageEnglish
JournalMalaria Journal
Volume11
Issue number139
Pages (from-to)1-7
Number of pages7
ISSN1475-2875
DOIs
Publication statusPublished - 2012

Keywords

  • Protozoal diseases
  • Malaria
  • Plasmodium falciparum
  • Vectors
  • Mosquitoes
  • Anopheles
  • Treatment
  • Artemisinin combination therapies (ACT)
  • Chlorproguanil
  • Dapsone
  • Artesunate
  • Children
  • Hemoglobin
  • Risk factors
  • G6PD deficiency
  • Randomized clinical trials
  • Africa-General
  • Author
  • PDF

Fingerprint

Dive into the research topics of 'Glucose-6-phosphate dehydrogenase deficiency, chlorproguanil-dapsone with artesunate and post-treatment haemolysis in African children treated for uncomplicated malaria'. Together they form a unique fingerprint.

Cite this